Sakkas Giorgos K, Krase Argiro A, Giannaki Christoforos D, Karatzaferi Christina
Giorgos K Sakkas, Christina Karatzaferi, Faculty of Sport and Health Sciences, University of St Mark and St John, Plymouth PL6 8BH, United Kingdom.
World J Nephrol. 2017 May 6;6(3):119-122. doi: 10.5527/wjn.v6.i3.119.
Chronic renal disease is associated with advanced age, diabetes, hypertension, obesity, musculoskeletal problems and cardiovascular disease, the latter being the main cause of mortality in patients receiving haemodialysis (HD). Cooled dialysate (35 °C-36 °C) is recently employed to reduce the incidence of intradialytic hypotension in patients on chronic HD. The studies to date that have evaluated cooled dialysate are limited, however, data suggest that cooled dialysate improves hemodynamic tolerability of dialysis, minimizes hypotension and exerts a protective effect over major organs including the heart and brain. The current evidence-based review is dealing with the protective effect of cold dialysis and the benefits of it in aspects affecting patients' quality of care and life. There is evidence to suggest that cold dialysis can reduce cardiovascular mortality. However, large multicentre randomized clinical trials are urgently needed to provide further supporting evidence in order to incorporate cold dialysis in routine clinical practice.
慢性肾病与高龄、糖尿病、高血压、肥胖、肌肉骨骼问题和心血管疾病相关,后者是接受血液透析(HD)患者的主要死亡原因。最近采用冷却透析液(35°C - 36°C)来降低慢性血液透析患者透析中低血压的发生率。然而,迄今为止评估冷却透析液的研究有限,不过数据表明,冷却透析液可改善透析的血流动力学耐受性,将低血压降至最低,并对包括心脏和大脑在内的主要器官发挥保护作用。当前基于证据的综述探讨了低温透析的保护作用及其在影响患者护理质量和生活方面的益处。有证据表明低温透析可降低心血管死亡率。然而,迫切需要大型多中心随机临床试验来提供进一步的支持证据,以便将低温透析纳入常规临床实践。